DAWN: Cowen Downgrades Day One Biopharmaceuticals to Hold March 2026

On March 6, 2026 Cowen & Co. cut Day One Biopharmaceuticals, Inc. (DAWN) from Buy → Hold, marking the lead change in the DAWN analyst rating landscape. The downgrade cites acquisition value and a reassessment of near-term upside while Oppenheimer maintained a Perform rating the same day. Investors should note the timing and the shift in price expectations as we track market reaction and analyst consensus.